Comparison of the real-world costs associated with different treatment patterns in adults initiating apremilast or biologics for the treatment of psoriasis

8561 Background: Atezolizumab plus chemotherapy was the first CIT combination regimen approved for 1L treatment of ES-SCLC in 2019. This study investigated patient characteristics and treatment patterns for patients with ES-SCLC receiving this regimen in the real-world community oncology setting. Methods: This was a retrospective study including adult patients diagnosed with ES-SCLC between 01-Oct-2018 (after IMpower 133 publication in NEJM Sep-2018) and 31-Dec-2019, with follow-up through 31-March-2020 using The US Oncology Network electronic health records data. Descriptive analyses of patient characteristics and treatment patterns were conducted, with Kaplan-Meier (K-M) methods used to assess time to treatment discontinuation (TTD) and time to next treatment/death (TTNT). Results: Of the 408 patients included in this study, 267 (71.4%) received atezo+carboplatin+etoposide (Atezo+Chemo), 80 (21.4%) received carboplatin+etoposide (Chemo only) and the rest received other regimens. The Atezo+Chemo patients in the real-world cohort compared with the IMpower 133 trial (n = 201) were older (median age 68 vs. 64 years) and included fewer males (45% vs. 64%), fewer white race (73% vs. 81%), more patients with brain metastases at baseline (23% vs. 9%), and more patients with worse ECOG (2/3) performance-status score (24% vs. 0%). The median follow-up, TTD, and TTNT in months (mo) for the real-world cohort are presented in the table alongside the best comparable measures reported for the trial. Conclusions: Most patients in this real-world ES-SCLC cohort received the Atezo+Chemo regimen in the 1L setting. While the follow-up was much shorter and patients had worse baseline characteristics (age, brain metastases, ECOG) in the real-world setting compared to the IMpower 133 trial, the real-world median TTD in this descriptive analysis was found to be in line with the median duration of treatment in the trial. Further research with longer follow-up comparing the real-world effectiveness of the CIT and chemo regimens is needed.[Table: see text]

Download Full-text

Abstract P4-14-03: What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?

10.1158/1538-7445.sabcs15-p4-14-03 ◽

2016 ◽

Cited By ~ 1

Author(s):

M Cloutier ◽

A Guerin ◽

J Heroux ◽

B Emond ◽

EQ Wu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Real World ◽

Metastatic Breast ◽

Medical Costs ◽

Treatment Patterns ◽

Trastuzumab Emtansine ◽

The Real

Download Full-text

Validity of social media for assessing treatment patterns in oncology patients: a case study in melanoma

JAMIA Open ◽

10.1093/jamiaopen/ooz013 ◽

2019 ◽

Vol 2 (4) ◽

pp. 416-422

Author(s):

Laura McDonald ◽

Varun Behl ◽

Vijayarakhavan Sundar ◽

Faisal Mehmud ◽

Bill Malcolm ◽

...

Keyword(s):

Social Media ◽

Confidence Intervals ◽

Real World ◽

Unmet Need ◽

Data Access ◽

Treatment Patterns ◽

Patient Treatment ◽

Real World Data ◽

The Real ◽

Third Line

Abstract There is a need to understand how patients are managed in the real world to better understand disease burden and unmet need. Traditional approaches to gather these data include the use of electronic medical record (EMR) or claims databases; however, in many cases data access policies prevent rapid insight gathering. Social media may provide a potential source of real-world data to assess treatment patterns, but the limitations and biases of doing so have not yet been evaluated. Here, we assessed whether patient treatment patterns extracted from publicly available patient forums compare to results from more traditional EMR and claims databases. We observed that the 95% confidence intervals of proportions of treatments received at first, second, and third line for advanced/metastatic melanoma generated from unstructured social media data overlapped with 95% confidence intervals from proportions obtained from 1 or more traditional EMR/Claims databases. Social media may offer a valid data option to understand treatment patterns in the real world.

Download Full-text

PCN214 UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS OF FOLLICULAR LYMPHOMA PATIENTS IN EU5 MARKETS

Value in Health ◽

10.1016/j.jval.2019.04.336 ◽

2019 ◽

Vol 22 ◽

pp. S96

Author(s):

A. Rider ◽

A. Bailey ◽

T. Bacon ◽

J. Garside

Keyword(s):

Follicular Lymphoma ◽

Real World ◽

Clinical Characteristics ◽

Treatment Patterns ◽

The Real

Download Full-text

Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.7090 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 7090-7090

Author(s):

A. Guérin ◽

A. Guo ◽

D. Williams ◽

A. P. Yu ◽

E. Wu ◽

...

Keyword(s):

Chronic Myelogenous Leukemia ◽

Dose Escalation ◽

Real World ◽

Philadelphia Chromosome ◽

Treatment Patterns ◽

Data Availability ◽

Myelogenous Leukemia ◽

Administrative Claims ◽

Dose Increase ◽

The Real

7090 Background: Imatinib is the first-line therapy for Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Patients with suboptimal responses may have the dose of imatinib escalated or may be switched to an alternative kinase inhibitor such as dasatinib. The aim of this study is to examine the real-world treatment patterns of imatinib and dasatinib in CML patients. Methods: Two large U.S. administrative claims databases from January 1999 to March 2008 were combined (MarketScan and Ingenix Impact) to extract de-identified information of patients diagnosed with CML (ICD-9 code: 205.1) who were initiated on imatinib. Patients were followed from the first observed imatinib prescription to the end of data availability. Patients who increased imatinib dose to >400 mg/day were defined as dose escalators, while patients who initiated on imatinib and further switched to dasatinib were considered as switchers. Rates of imatinib dose escalation and switching to dasatinib were estimated. Kaplan-Meier (KM) survival analyses were used to estimate the rate of imatinib discontinuation, defined as a lack of imatinib supply for at least 90 days. Among switchers, the rate of switching back to imatinib was also estimated using KM survival analysis. Results: Among the 5,159 CML patients initiated with imatinib, 1,144 patients either had dose escalation of imatinib (839) or were switched to dasatinib (305) during the study period. Of the 5,159 patients, 12.1% patients discontinued imatinib by the end of the first year, and 25.4% discontinued by the end of the third year. Among the 305 switchers, 115 (37.7%) had an imatinib dose increase prior to the switch, and 66 (21.6%) were escalated to 800 mg of imatinib before switching. 51 patients (16.7%) had used imatinib for <6 months before switching, and 17.1% switched back to imatinib within 6 months of dasatinib treatment. Conclusions: This study showed that great variability was observed in the real world treatment pattern of CML patients. Most CML patients who initiated on imatinib did not dose increase or switch during the study period. Of those who switched to dasatinib, most did not attempt to increase the dose before switching, and a sizeable portion of patients had to switch back to imatinib. [Table: see text]

Download Full-text